Can chronic psoriatic arthritis cause an elevated coronary calcium score?

Yes, Chronic Psoriatic Arthritis Can Cause Elevated Coronary Calcium

Psoriatic arthritis (PsA) is independently associated with increased coronary artery calcification (CAC), with patients showing 1.28 times higher odds of having any coronary calcium (CACS >0) compared to controls, even after adjusting for traditional cardiovascular risk factors 1. This relationship reflects the chronic systemic inflammation inherent to PsA driving accelerated atherosclerosis.

The Evidence for PsA and Coronary Calcification

Direct Association with Coronary Calcium

Multiple high-quality studies demonstrate that PsA patients have significantly elevated coronary calcium scores:

• A 2021 Danish national registry study of 46,022 patients found PsA patients had an adjusted odds ratio of 1.28 (1.00-1.64) for CACS >0, indicating any detectable coronary calcification 1
• A 2022 meta-analysis of 16 studies involving 3,039 psoriasis patients (including those with PsA) showed an overall odds ratio of 1.54 for coronary calcification presence 2
• The association persists even after matching or adjusting for conventional cardiovascular risk factors like hypertension, diabetes, dyslipidemia, and smoking 1, 2

Why PsA Specifically Increases Risk

The 2019 AAD-NPF guidelines explicitly identify psoriatic arthritis as an independent risk factor for cardiovascular events, with a hazard ratio of 1.63 (1.15-2.32) 3. This elevated risk stems from:

• Chronic systemic inflammation with elevated inflammatory cytokines (TNF-α, IL-17, IL-6) that promote endothelial dysfunction and atherosclerotic plaque formation 4, 5
• Higher prevalence of traditional CV risk factors: PsA patients show prevalence ratios of 1.3 for hypertension, 1.5 for diabetes, and 1.2 for hyperlipidemia compared to controls 4
• Increased subclinical atherosclerosis markers: PsA patients demonstrate greater intimal-medial thickness (IMT) that correlates with disease activity parameters 4

Clinical Implications and Screening Recommendations

Who Should Be Screened

The 2019 AHA/ACC cholesterol guidelines specifically recognize chronic inflammatory disorders (including PsA) as conditions that enhance cardiovascular risk 6. They recommend:

• Assessing traditional ASCVD risk factors early in the disease process
• Using CAC scoring when uncertainty exists about statin therapy initiation or if the patient has had statin side effects
• CAC score ≥100 Agatston units or ≥75th percentile for age/sex supports initiating statin therapy 6

Age-Dependent Risk

The association between psoriasis/PsA and coronary calcification is stronger in younger patients (mean age <50 years, OR: 2.63) compared to older patients (≥50 years, OR: 1.24) 2. This suggests that:

• Younger PsA patients experience accelerated atherosclerosis beyond what traditional risk scores predict
• Early screening may be particularly valuable in this population
• Traditional risk calculators likely underestimate actual cardiovascular risk in PsA patients 6

Important Caveats and Pitfalls

CAC Reflects Disease Burden, Not Just Risk

Recent evidence shows that in well-controlled PsA patients on biologic therapy, there may be a positive correlation between treatment duration and calcified plaque burden 7. This paradoxical finding suggests:

• Calcification may represent plaque stabilization rather than progression in treated patients
• Non-calcified (vulnerable) plaques may be converting to calcified (stable) plaques with anti-inflammatory treatment
• CAC scoring alone doesn't distinguish between active disease progression and therapeutic stabilization

The Inflammation-Lipid Paradox

PsA patients with highly active disease often have lower total cholesterol and LDL levels despite elevated cardiovascular risk 8. This means:

• Standard lipid panels may underestimate risk during active inflammation
• Lipid assessment should ideally occur when disease is stable or in remission 8
• The TC/HDL ratio is more predictive than individual lipid components 8

Treatment Considerations

Systemic anti-inflammatory therapy for PsA may reduce cardiovascular risk:

• TNF inhibitors show hazard ratios of 0.50 for major cardiovascular events 3
• Methotrexate demonstrates cardioprotective effects (HR 0.53) 3
• However, even well-controlled PsA patients can have significant coronary disease - one study found 74% had coronary plaques and 15% had silent myocardial ischemia despite median PASI of 0 7

Practical Approach

For PsA patients with elevated coronary calcium:

1. Recognize PsA as an independent cardiovascular risk enhancer requiring aggressive risk factor modification 4, 6, 5

2. Optimize disease control with systemic anti-inflammatory therapy, as this may reduce cardiovascular events 3

3. Initiate or intensify statin therapy if CAC score ≥100 or ≥75th percentile for age/sex 6

4. Address all modifiable risk factors: smoking cessation, blood pressure control, diabetes management, weight reduction 4

5. Consider cardiology referral for patients with high CAC scores (≥400), especially if symptomatic or with multiple risk factors 7, 9

6. Monitor lipids when disease is stable, as active inflammation distorts lipid profiles 8

The bottom line: chronic psoriatic arthritis directly contributes to elevated coronary calcium through sustained systemic inflammation that accelerates atherosclerosis, independent of traditional cardiovascular risk factors.